Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + XELOX vs XELOX as Adjuvant Therapy for Colorectal Cancer Liver Metastases
NCT00394992Phase 3Terminated
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Dec 2006
- Primary completion
- Aug 2013
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in colorectal cancer (CRC), sponsored by Dutch Colorectal Cancer Group. Primary endpoint: Disease-Free Survival at 3 years. Started Dec 2006; status: terminated.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00394992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00394992.